Last reviewed · How we verify
Roflumilast 0.3% topical foam
At a glance
| Generic name | Roflumilast 0.3% topical foam |
|---|---|
| Also known as | ZORYVE |
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Efficacy of Roflumilast Foam in HS (PHASE2)
- A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa (PHASE2)
- An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV) (PHASE2)
- Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (PHASE3)
- Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) (PHASE3)
- Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Roflumilast 0.3% topical foam CI brief — competitive landscape report
- Roflumilast 0.3% topical foam updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI